From Hunted To Hunter: Amgen Seeks Approval of Biosimilar To Humira
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech giant, a frequent target of early 351(k) submissions, announces its first application under the biosimilar pathway for ABP 501, which references AbbVie's commercially important TNF-inhibitor adalimumab.